Product Description: Gartisertib (VX-803) is an ATP-competitive, orally active, and selective ATR inhibitor, with a Ki of 50 of 8 nM. Antitumor activity[1][2].
Applications: Cancer-Kinase/protease
Formula: C25H29F2N9O3
References: [1]Frank T. Zenke, et al. Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy. Experimental and Molecular Therapeutics./[2]Gorecki L, et al. Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy. Pharmacol Ther. 2020 Feb 26:107518.
CAS Number: 1613191-99-3
Molecular Weight: 541.55
Compound Purity: 99.76
Research Area: Cancer
Solubility: DMSO : 25 mg/mL (ultrasonic)
Target: ATM/ATR